| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_96bb6fb81fbb886e7192677436bdddc6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74955dea096155a76276be97f0ec249d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_61487a13ef2a23abbf0ac2d73a21a33f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0b35e65b2beba22fba1c8bdbf70ce206 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1796
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-03 |
| filingDate |
2017-04-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_89cbb3e7c75928c4b1cb7ca36b3140b2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9178581c98454e9f8d172f58fe056792
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_883b7ceb6e8df28f43ac6ad3fb1f0f7d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bce795dba4834ac35867088ab9c1a5b |
| publicationDate |
2019-05-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2019142963-A1 |
| titleOfInvention |
Fgf21 c-terminal peptide optimization |
| abstract |
Disclosed herein are modified C-terminal fragments of FGF21 optimized for binding to Klotho β or antagonizing FGF21 activity. FGF21 peptides modified to comprise modifications to the C-terminal amino acid sequence are disclosed that have enhanced activity at the FGF21 receptor. Additionally, conjugates formed between the optimized FGF21 peptide fragments and insulin like peptides or nuclear hormone receptor ligands are provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11566059-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11365228-B2 |
| priorityDate |
2016-04-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |